GLOBAL BLOOD PLASMA MARKET FORECAST 2018-2026
KEY FINDINGS
The Global Blood Plasma market is driven by factors like growing patient pool for haemophilia, the high prevalence of alpha-1 antitrypsin deficiency and the advent of new therapeutic indications. By the end of the forecast period of 2018-2026, the market is slated to account for a CAGR of 6.62%.
MARKET INSIGHTS
The global blood plasma market is segmented according to the blood type, applications and end-users. The blood type segment includes Intravenous immunoglobulin, Immunoglobulin, Subcutaneous immunoglobulin, and other immunoglobulin type along with Hyperimmune, Albumin, Coagulation factor concentrates and other plasma fractionation products. Blood plasma finds its application in oncology, immunology, pulmonology, transplantation, rheumatology, neurology, haematology and other applications. The end-users for this market are academic institutions, research laboratories and hospitals and clinics.
REGIONAL INSIGHTS
Regional segmentation of the global blood plasma market is done into North America, Europe, Asia-Pacific and rest of the world. The North American region rules this market and is expected to continue having the upper hand over other regional markets throughout the projected years of 2018-2026. Increase in the prevalence of disorders like leukaemia, haemophilia, and other blood disorders are expected to increase the market demand further in this region. The highest CAGR by the end of the forecast period is expected from the Asia-Pacific market. Several non-profit organizations such as the Asia-Pacific Blood Network (APBN) are actively involved in ensuring that there is an increased plasma supply in the APAC region.
COMPETITIVE INSIGHTS
Leading companies such as Adma Biologics Inc, Arthrex, Baxter International Inc, Biotest Ag, Cerus Corp, China Biologic Products Inc, Csl Ltd, General Electric Co, Grifols International S.A, Octopharma Ag, and Shire Plc are actively engaged in this market.
The Global Blood Plasma market is driven by factors like growing patient pool for haemophilia, the high prevalence of alpha-1 antitrypsin deficiency and the advent of new therapeutic indications. By the end of the forecast period of 2018-2026, the market is slated to account for a CAGR of 6.62%.
MARKET INSIGHTS
The global blood plasma market is segmented according to the blood type, applications and end-users. The blood type segment includes Intravenous immunoglobulin, Immunoglobulin, Subcutaneous immunoglobulin, and other immunoglobulin type along with Hyperimmune, Albumin, Coagulation factor concentrates and other plasma fractionation products. Blood plasma finds its application in oncology, immunology, pulmonology, transplantation, rheumatology, neurology, haematology and other applications. The end-users for this market are academic institutions, research laboratories and hospitals and clinics.
REGIONAL INSIGHTS
Regional segmentation of the global blood plasma market is done into North America, Europe, Asia-Pacific and rest of the world. The North American region rules this market and is expected to continue having the upper hand over other regional markets throughout the projected years of 2018-2026. Increase in the prevalence of disorders like leukaemia, haemophilia, and other blood disorders are expected to increase the market demand further in this region. The highest CAGR by the end of the forecast period is expected from the Asia-Pacific market. Several non-profit organizations such as the Asia-Pacific Blood Network (APBN) are actively involved in ensuring that there is an increased plasma supply in the APAC region.
COMPETITIVE INSIGHTS
Leading companies such as Adma Biologics Inc, Arthrex, Baxter International Inc, Biotest Ag, Cerus Corp, China Biologic Products Inc, Csl Ltd, General Electric Co, Grifols International S.A, Octopharma Ag, and Shire Plc are actively engaged in this market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. PROVISION OF BETTER HEALTHCARE INFRASTRUCTURE IN DEVELOPED COUNTRIES
3.2.2. IMMUNOGLOBULIN BLOOD TYPE TO HOLD THE LARGEST MARKET SHARE BY 2026
3.2.3. TRANSPLANTATION IS ANTICIPATED TO BE THE FASTEST GROWING APPLICATION IN BLOOD PLASMA
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
4.1.2. EXPLOITATION OF NEW THERAPEUTIC INDICATIONS
4.1.3. AUGMENTED GERIATRIC POPULATION
4.1.4. RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
4.1.5. INCREASE IN PATIENT POOL FOR HEMOPHILIA TREATMENT
4.2. RESTRAINTS
4.2.1. SWELLING USE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
4.2.2. HIGH COSTS OF BLOOD PLASMA TREATMENTS
4.2.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
4.3. OPPORTUNITIES
4.3.1. RISING INCIDENCE OF HEMOPHILIA
4.3.2. GROWING PUBLIC AWARENESS
4.3.3. NEW PRODUCT OPPORTUNITIES
4.4. CHALLENGES
4.4.1. SPREAD OF PATHOGENIC CONTAMINANTS
4.4.2. HIGH REGULATIONS IN THE MARKET
5. MARKET BY MODE OF DELIVERY
5.1. INFUSION SOLUTIONS
5.2. GELS
5.3. SPRAYS
5.4. BIOMEDICAL SEALANTS
6. MARKET SEGMENTATION
6.1. MARKET BY BLOOD TYPE 2018-2026
6.1.1. IMMUNOGLOBULIN
6.2. INTRAVENOUS IMMUNOGLOBULIN
6.3. SUBCUTANEOUS IMMUNOGLOBULIN
6.4. OTHER IMMUNOGLOBULIN TYPE
6.4.1. ALBUMIN
6.4.2. HYPERIMMUNES
6.4.3. COAGULATION FACTOR CONCENTRATES
6.4.4. OTHER PLASMA FRACTIONATION PRODUCTS
6.5. MARKET BY APPLICATION 2018-2026
6.5.1. IMMUNOLOGY
6.5.2. ONCOLOGY
6.5.3. PULMONOLOGY
6.5.4. RHEUMATOLOGY
6.5.5. TRANSPLANTATION
6.5.6. NEUROLOGY
6.5.7. HEMATOLOGY
6.5.8. OTHER APPLICATIONS
6.6. MARKET BY END USER 2018-2026
6.6.1. HOSPITALS AND CLINICS
6.6.2. RESEARCH LABORATORIES
6.6.3. ACADEMIC INSTITUTIONS
7. KEY ANALYTICS
7.1. PORTER’S FIVE FORCES ANALYSIS
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTES
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. THREAT OF RIVALRY
7.2. PLASMA THERAPEUTICS REGULATION
7.3. MARKET TRENDS
7.4. PATENT ANALYSIS
7.5. REGULATORY AGENCIES
7.6. CLINICAL GUIDELINES
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. THE UNITED STATES
8.1.2. CANADA
8.2. EUROPE
8.2.1. FRANCE
8.2.2. GERMANY
8.2.3. THE UNITED KINGDOM
8.2.4. REST OF EUROPE
8.3. ASIA-PACIFIC
8.3.1. JAPAN
8.3.2. CHINA
8.3.3. AUSTRALIA
8.3.4. INDIA
8.3.5. REST OF ASIA-PACIFIC
8.4. REST OF WORLD
8.4.1. LATIN AMERICA
8.4.2. MIDDLE EAST AND AFRICA
9. COMPANY PROFILES
9.1. ADMA BIOLOGICS INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.2. ARTHREX
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC MOVES
9.3. BAXTER INTERNATIONAL INC.
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BIOTEST AG
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVES
9.5. CERUS CORP.
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.6. CHINA BIOLOGIC PRODUCTS INC.
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC INITIATIVES
9.7. CSL LTD.
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. PRODUCT PORTFOLIO
9.8. GENERAL ELECTRIC CO.
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SWOT ANALYSIS
9.8.4. STRATEGIC INITIATIVES
9.9. GRIFOLS INTERNATIONAL S.A.
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVES
9.10. OCTOPHARMA AG
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.11. SHIRE PLC
9.11.1. COMPANY OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC INITIATIVES
TABLE LIST
TABLE 1 GLOBAL BLOOD PLASMA MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 BLOOD PLASMA COMPONENTS
TABLE 3 GLOBAL BLOOD PLASMA MARKET BY BLOOD TYPE 2018-2026 ($ MILLION)
TABLE 4 GLOBAL BLOOD PLASMA MARKET IN IMMUNOGLOBULIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 5 GLOBAL BLOOD PLASMA MARKET IN IMMUNOGLOBULIN BY TYPES 2018-2026 ($ MILLION)
TABLE 6 GLOBAL IMMUNOGLOBULIN MARKET IN INTRAVENOUS IMMUNOGLOBULIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 7 GLOBAL IMMUNOGLOBULIN MARKET IN SUBCUTANEOUS IMMUNOGLOBULIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 8 GLOBAL IMMUNOGLOBULIN MARKET IN OTHER IMMUNOGLOBULIN TYPE BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 GLOBAL BLOOD PLASMA MARKET IN ALBUMIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 10 GLOBAL BLOOD PLASMA MARKET IN HYPERIMMUNES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 11 GLOBAL BLOOD PLASMA MARKET IN COAGULATION FACTOR CONCENTRATES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 12 GLOBAL BLOOD PLASMA MARKET IN OTHER PLASMA FRACTIONATION PRODUCTS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 13 PROTEASE INHIBITORS USED IN THE HIV INFECTION TREATMENT
TABLE 14 GLOBAL BLOOD PLASMA MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 15 GLOBAL BLOOD PLASMA MARKET IN IMMUNOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 16 GLOBAL BLOOD PLASMA MARKET IN ONCOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 17 GLOBAL BLOOD PLASMA MARKET IN PULMONOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 18 GLOBAL BLOOD PLASMA MARKET IN RHEUMATOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 19 GLOBAL BLOOD PLASMA MARKET IN TRANSPLANTATION BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 20 GLOBAL BLOOD PLASMA MARKET IN NEUROLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 21 GLOBAL BLOOD PLASMA MARKET IN HEMATOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 22 GLOBAL BLOOD PLASMA MARKET IN OTHER APPLICATIONS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 23 GLOBAL BLOOD PLASMA MARKET BY END USER 2018-2026 ($ MILLION)
TABLE 24 GLOBAL BLOOD PLASMA MARKET IN HOSPITALS AND CLINICS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 25 GLOBAL BLOOD PLASMA MARKET IN RESEARCH LABORATORIES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 26 GLOBAL BLOOD PLASMA MARKET IN ACADEMIC INSTITUTIONS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 27 BLOOD PLASMA PRODUCTS NUMBER OF PATENTS ISSUED 2014–2016
TABLE 28 BLOOD PLASMA PRODUCTS PATENTS ISSUED BY GEOGRAPHY 2014-2016
TABLE 29 GLOBAL BLOOD PLASMA MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 30 NORTH AMERICA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
TABLE 31 EUROPE BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
TABLE 32 ASIA-PACIFIC BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
TABLE 33 REST OF WORLD BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 GLOBAL BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 2 IMMUNOGLOBULIN INFUSIONS SIDE EFFECTS
FIGURE 3 ROLE OF FIBRIN SEALANT IN COAGULATION CASCADE
FIGURE 4 GLOBAL BLOOD PLASMA MARKET IN IMMUNOGLOBULIN 2018-2026 ($ MILLION)
FIGURE 5 GLOBAL BLOOD PLASMA MARKET IN ALBUMIN 2018-2026 ($ MILLION)
FIGURE 6 HYPERIMMUNES ISOLATION PROCESS
FIGURE 7 GLOBAL BLOOD PLASMA MARKET IN HYPERIMMUNES 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL BLOOD PLASMA MARKET IN COAGULATION FACTOR CONCENTRATES 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL BLOOD PLASMA MARKET IN OTHER PLASMA FRACTIONATION PRODUCTS 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL BLOOD PLASMA MARKET IN IMMUNOLOGY 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL BLOOD PLASMA MARKET IN ONCOLOGY 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL BLOOD PLASMA MARKET IN PULMONOLOGY 2018-2026 ($ MILLION)
FIGURE 13 LUPUS INFECTION SYMPTOMS
FIGURE 14 GLOBAL BLOOD PLASMA MARKET IN RHEUMATOLOGY 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL BLOOD PLASMA MARKET IN TRANSPLANTATION 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL BLOOD PLASMA MARKET IN NEUROLOGY 2018-2026 ($ MILLION)
FIGURE 17 GLOBAL BLOOD PLASMA MARKET IN HEMATOLOGY 2018-2026 ($ MILLION)
FIGURE 18 GLOBAL BLOOD PLASMA MARKET IN OTHER APPLICATIONS 2018-2026 ($ MILLION)
FIGURE 19 GLOBAL BLOOD PLASMA MARKET IN HOSPITALS AND CLINICS 2018-2026 ($ MILLION)
FIGURE 20 GLOBAL BLOOD PLASMA MARKET IN RESEARCH LABORATORIES 2018-2026 ($ MILLION)
FIGURE 21 GLOBAL BLOOD PLASMA MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 22 BLOOD PLASMA PRODUCTS PATENTS SHARES BY COUNTRY 2014-2016 (%)
FIGURE 23 THE UNITED STATES BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 24 CANADA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 25 FRANCE BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 26 GERMANY BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 27 THE UNITED KINGDOM BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 28 REST OF EUROPE BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 29 JAPAN BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 30 CHINA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 31 AUSTRALIA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 32 INDIA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 33 REST OF ASIA-PACIFIC BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 34 LATIN AMERICA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. PROVISION OF BETTER HEALTHCARE INFRASTRUCTURE IN DEVELOPED COUNTRIES
3.2.2. IMMUNOGLOBULIN BLOOD TYPE TO HOLD THE LARGEST MARKET SHARE BY 2026
3.2.3. TRANSPLANTATION IS ANTICIPATED TO BE THE FASTEST GROWING APPLICATION IN BLOOD PLASMA
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
4.1.2. EXPLOITATION OF NEW THERAPEUTIC INDICATIONS
4.1.3. AUGMENTED GERIATRIC POPULATION
4.1.4. RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
4.1.5. INCREASE IN PATIENT POOL FOR HEMOPHILIA TREATMENT
4.2. RESTRAINTS
4.2.1. SWELLING USE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
4.2.2. HIGH COSTS OF BLOOD PLASMA TREATMENTS
4.2.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
4.3. OPPORTUNITIES
4.3.1. RISING INCIDENCE OF HEMOPHILIA
4.3.2. GROWING PUBLIC AWARENESS
4.3.3. NEW PRODUCT OPPORTUNITIES
4.4. CHALLENGES
4.4.1. SPREAD OF PATHOGENIC CONTAMINANTS
4.4.2. HIGH REGULATIONS IN THE MARKET
5. MARKET BY MODE OF DELIVERY
5.1. INFUSION SOLUTIONS
5.2. GELS
5.3. SPRAYS
5.4. BIOMEDICAL SEALANTS
6. MARKET SEGMENTATION
6.1. MARKET BY BLOOD TYPE 2018-2026
6.1.1. IMMUNOGLOBULIN
6.2. INTRAVENOUS IMMUNOGLOBULIN
6.3. SUBCUTANEOUS IMMUNOGLOBULIN
6.4. OTHER IMMUNOGLOBULIN TYPE
6.4.1. ALBUMIN
6.4.2. HYPERIMMUNES
6.4.3. COAGULATION FACTOR CONCENTRATES
6.4.4. OTHER PLASMA FRACTIONATION PRODUCTS
6.5. MARKET BY APPLICATION 2018-2026
6.5.1. IMMUNOLOGY
6.5.2. ONCOLOGY
6.5.3. PULMONOLOGY
6.5.4. RHEUMATOLOGY
6.5.5. TRANSPLANTATION
6.5.6. NEUROLOGY
6.5.7. HEMATOLOGY
6.5.8. OTHER APPLICATIONS
6.6. MARKET BY END USER 2018-2026
6.6.1. HOSPITALS AND CLINICS
6.6.2. RESEARCH LABORATORIES
6.6.3. ACADEMIC INSTITUTIONS
7. KEY ANALYTICS
7.1. PORTER’S FIVE FORCES ANALYSIS
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTES
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. THREAT OF RIVALRY
7.2. PLASMA THERAPEUTICS REGULATION
7.3. MARKET TRENDS
7.4. PATENT ANALYSIS
7.5. REGULATORY AGENCIES
7.6. CLINICAL GUIDELINES
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. THE UNITED STATES
8.1.2. CANADA
8.2. EUROPE
8.2.1. FRANCE
8.2.2. GERMANY
8.2.3. THE UNITED KINGDOM
8.2.4. REST OF EUROPE
8.3. ASIA-PACIFIC
8.3.1. JAPAN
8.3.2. CHINA
8.3.3. AUSTRALIA
8.3.4. INDIA
8.3.5. REST OF ASIA-PACIFIC
8.4. REST OF WORLD
8.4.1. LATIN AMERICA
8.4.2. MIDDLE EAST AND AFRICA
9. COMPANY PROFILES
9.1. ADMA BIOLOGICS INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.2. ARTHREX
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC MOVES
9.3. BAXTER INTERNATIONAL INC.
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BIOTEST AG
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVES
9.5. CERUS CORP.
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.6. CHINA BIOLOGIC PRODUCTS INC.
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. STRATEGIC INITIATIVES
9.7. CSL LTD.
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. PRODUCT PORTFOLIO
9.8. GENERAL ELECTRIC CO.
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SWOT ANALYSIS
9.8.4. STRATEGIC INITIATIVES
9.9. GRIFOLS INTERNATIONAL S.A.
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVES
9.10. OCTOPHARMA AG
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.11. SHIRE PLC
9.11.1. COMPANY OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC INITIATIVES
TABLE LIST
TABLE 1 GLOBAL BLOOD PLASMA MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 BLOOD PLASMA COMPONENTS
TABLE 3 GLOBAL BLOOD PLASMA MARKET BY BLOOD TYPE 2018-2026 ($ MILLION)
TABLE 4 GLOBAL BLOOD PLASMA MARKET IN IMMUNOGLOBULIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 5 GLOBAL BLOOD PLASMA MARKET IN IMMUNOGLOBULIN BY TYPES 2018-2026 ($ MILLION)
TABLE 6 GLOBAL IMMUNOGLOBULIN MARKET IN INTRAVENOUS IMMUNOGLOBULIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 7 GLOBAL IMMUNOGLOBULIN MARKET IN SUBCUTANEOUS IMMUNOGLOBULIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 8 GLOBAL IMMUNOGLOBULIN MARKET IN OTHER IMMUNOGLOBULIN TYPE BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 9 GLOBAL BLOOD PLASMA MARKET IN ALBUMIN BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 10 GLOBAL BLOOD PLASMA MARKET IN HYPERIMMUNES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 11 GLOBAL BLOOD PLASMA MARKET IN COAGULATION FACTOR CONCENTRATES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 12 GLOBAL BLOOD PLASMA MARKET IN OTHER PLASMA FRACTIONATION PRODUCTS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 13 PROTEASE INHIBITORS USED IN THE HIV INFECTION TREATMENT
TABLE 14 GLOBAL BLOOD PLASMA MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 15 GLOBAL BLOOD PLASMA MARKET IN IMMUNOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 16 GLOBAL BLOOD PLASMA MARKET IN ONCOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 17 GLOBAL BLOOD PLASMA MARKET IN PULMONOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 18 GLOBAL BLOOD PLASMA MARKET IN RHEUMATOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 19 GLOBAL BLOOD PLASMA MARKET IN TRANSPLANTATION BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 20 GLOBAL BLOOD PLASMA MARKET IN NEUROLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 21 GLOBAL BLOOD PLASMA MARKET IN HEMATOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 22 GLOBAL BLOOD PLASMA MARKET IN OTHER APPLICATIONS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 23 GLOBAL BLOOD PLASMA MARKET BY END USER 2018-2026 ($ MILLION)
TABLE 24 GLOBAL BLOOD PLASMA MARKET IN HOSPITALS AND CLINICS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 25 GLOBAL BLOOD PLASMA MARKET IN RESEARCH LABORATORIES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 26 GLOBAL BLOOD PLASMA MARKET IN ACADEMIC INSTITUTIONS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 27 BLOOD PLASMA PRODUCTS NUMBER OF PATENTS ISSUED 2014–2016
TABLE 28 BLOOD PLASMA PRODUCTS PATENTS ISSUED BY GEOGRAPHY 2014-2016
TABLE 29 GLOBAL BLOOD PLASMA MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 30 NORTH AMERICA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
TABLE 31 EUROPE BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
TABLE 32 ASIA-PACIFIC BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
TABLE 33 REST OF WORLD BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 GLOBAL BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 2 IMMUNOGLOBULIN INFUSIONS SIDE EFFECTS
FIGURE 3 ROLE OF FIBRIN SEALANT IN COAGULATION CASCADE
FIGURE 4 GLOBAL BLOOD PLASMA MARKET IN IMMUNOGLOBULIN 2018-2026 ($ MILLION)
FIGURE 5 GLOBAL BLOOD PLASMA MARKET IN ALBUMIN 2018-2026 ($ MILLION)
FIGURE 6 HYPERIMMUNES ISOLATION PROCESS
FIGURE 7 GLOBAL BLOOD PLASMA MARKET IN HYPERIMMUNES 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL BLOOD PLASMA MARKET IN COAGULATION FACTOR CONCENTRATES 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL BLOOD PLASMA MARKET IN OTHER PLASMA FRACTIONATION PRODUCTS 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL BLOOD PLASMA MARKET IN IMMUNOLOGY 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL BLOOD PLASMA MARKET IN ONCOLOGY 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL BLOOD PLASMA MARKET IN PULMONOLOGY 2018-2026 ($ MILLION)
FIGURE 13 LUPUS INFECTION SYMPTOMS
FIGURE 14 GLOBAL BLOOD PLASMA MARKET IN RHEUMATOLOGY 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL BLOOD PLASMA MARKET IN TRANSPLANTATION 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL BLOOD PLASMA MARKET IN NEUROLOGY 2018-2026 ($ MILLION)
FIGURE 17 GLOBAL BLOOD PLASMA MARKET IN HEMATOLOGY 2018-2026 ($ MILLION)
FIGURE 18 GLOBAL BLOOD PLASMA MARKET IN OTHER APPLICATIONS 2018-2026 ($ MILLION)
FIGURE 19 GLOBAL BLOOD PLASMA MARKET IN HOSPITALS AND CLINICS 2018-2026 ($ MILLION)
FIGURE 20 GLOBAL BLOOD PLASMA MARKET IN RESEARCH LABORATORIES 2018-2026 ($ MILLION)
FIGURE 21 GLOBAL BLOOD PLASMA MARKET IN ACADEMIC INSTITUTIONS 2018-2026 ($ MILLION)
FIGURE 22 BLOOD PLASMA PRODUCTS PATENTS SHARES BY COUNTRY 2014-2016 (%)
FIGURE 23 THE UNITED STATES BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 24 CANADA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 25 FRANCE BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 26 GERMANY BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 27 THE UNITED KINGDOM BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 28 REST OF EUROPE BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 29 JAPAN BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 30 CHINA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 31 AUSTRALIA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 32 INDIA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 33 REST OF ASIA-PACIFIC BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 34 LATIN AMERICA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA BLOOD PLASMA MARKET 2018-2026 ($ MILLION)
